Summary
Isofol Medical AB (5IU) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Isofol Medical AB ever had a stock split?
Isofol Medical AB Profile
| Biotechnology Industry | Healthcare Sector | Dr. Roger Tell M.D., Ph.D. CEO | XFRA Exchange | SE0009581051 ISIN |
| Sweden Country | 4 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Isofol Medical AB (publ) is a pivotal player in the biotechnology industry, focusing on the development, commercialization, and international sale of oncology drugs. Established in 2008 and headquartered in Gothenburg, Sweden, Isofol stands at the forefront of clinical stage biotech companies. Through its unwavering commitment to innovation in cancer treatment, the company seeks to offer new hope and enhanced therapeutic options for patients battling cancer, particularly those suffering from advanced colorectal cancer.
Products and Services
- Arfolitixorin
At the heart of Isofol Medical AB's product pipeline is arfolitixorin, a novel drug currently in a phase 3 clinical trial. This promising oncology drug is being developed primarily for the treatment of advanced colorectal cancer. Arfolitixorin represents a significant focal point of Isofol's research and development efforts, showcasing the company's commitment to advancing cancer treatment through innovative therapeutic solutions.
